IN2014MN01488A - - Google Patents

Info

Publication number
IN2014MN01488A
IN2014MN01488A IN1488MUN2014A IN2014MN01488A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A IN 1488MUN2014 A IN1488MUN2014 A IN 1488MUN2014A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A
Authority
IN
India
Prior art keywords
mixture
subunits
subunit
mol
relative
Prior art date
Application number
Other languages
English (en)
Inventor
Laura Akullian
Gui Liu
Timothy B Lowinger
Dennis Mcgillicuddy
Cheri Stevenson
John Van Duzer
Mao Yin
Aleksandr Yurkovetskiy
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of IN2014MN01488A publication Critical patent/IN2014MN01488A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
IN1488MUN2014 2011-12-23 2012-12-21 IN2014MN01488A (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580016P 2011-12-23 2011-12-23
US201261639654P 2012-04-27 2012-04-27
PCT/US2012/071477 WO2013096901A1 (en) 2011-12-23 2012-12-21 Pharmaceutical formulations for fumagillin derivative-phf conjugates

Publications (1)

Publication Number Publication Date
IN2014MN01488A true IN2014MN01488A (pl) 2015-04-17

Family

ID=48669583

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1488MUN2014 IN2014MN01488A (pl) 2011-12-23 2012-12-21

Country Status (9)

Country Link
US (1) US20130189218A1 (pl)
EP (1) EP2794582A1 (pl)
JP (1) JP2015503635A (pl)
KR (1) KR20140121827A (pl)
CN (1) CN104024236A (pl)
IN (1) IN2014MN01488A (pl)
TW (1) TW201332574A (pl)
UY (1) UY34542A (pl)
WO (1) WO2013096901A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
JP2017537893A (ja) 2014-10-31 2017-12-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗cs1抗体および抗体薬結合体
BR112017012377A2 (pt) 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
EP3230282A1 (en) 2014-12-09 2017-10-18 AbbVie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
WO2017095805A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗huLRRC15抗体薬物コンジュゲート及びその使用方法
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
EP3626273B1 (en) 2016-05-17 2020-12-30 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
WO2017210566A1 (en) 2016-06-03 2017-12-07 Novacyte, Inc. Polymer linkers and their uses
BR112018075644A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2018015268A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
US20190153107A1 (en) 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
PL3458479T4 (pl) 2016-06-08 2021-07-26 Abbvie Inc. Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
MX2018015274A (es) 2016-06-08 2019-10-07 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CN109562190A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
US20190343961A1 (en) 2016-06-08 2019-11-14 Abbvie Inc. Anti-egfr antibody drug conjugates
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
HUE073108T2 (hu) * 2018-07-03 2026-01-28 Fennec Pharmaceuticals Inc Anhidrid natrium-tioszulfat formulái
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
TW202120556A (zh) 2019-08-08 2021-06-01 美商再生元醫藥公司 新穎抗原結合分子型式
KR20220093363A (ko) 2019-11-05 2022-07-05 리제너론 파아마슈티컬스, 인크. N-말단 scFv 다중특이적 결합 분자
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
EP4114860A1 (en) 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
EP4420681A4 (en) * 2021-10-19 2025-02-26 Coherent Biopharma (Suzhou), Limited PREPARATION OF CONJUGATE DRUG, ITS PREPARATION METHOD AND ITS USE
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
NZ600039A (en) * 2007-11-28 2013-11-29 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
WO2010138719A1 (en) * 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers

Also Published As

Publication number Publication date
UY34542A (es) 2013-07-31
WO2013096901A8 (en) 2014-08-07
EP2794582A1 (en) 2014-10-29
US20130189218A1 (en) 2013-07-25
TW201332574A (zh) 2013-08-16
KR20140121827A (ko) 2014-10-16
CN104024236A (zh) 2014-09-03
WO2013096901A1 (en) 2013-06-27
JP2015503635A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
IN2014MN01488A (pl)
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
UA111820C2 (uk) Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора
MX2018008061A (es) Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
CY1120557T1 (el) Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων
GB201008902D0 (en) Membrane enhanced polymer sythesis
MX347644B (es) Macromoleculas estrella para el cuidado personal y del hogar.
EP2812438A4 (en) MANIPULATED STRAIN OF ESCHERICHIA COLI FOR THE PREPARATION OF POLY-R-3 HYDROXYALKONOATE POLYMERS WITH A DEFINED MONOMER COMPOSITION AND METHODS BASED ON IT
MX2010009154A (es) Moleculas conjugadas del factor viii.
IN2014DN00101A (pl)
EP2621480A4 (en) CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY
WO2012135025A3 (en) Conjugated lipomers and uses thereof
EP2635265A4 (en) NOVEL CYCLIC AMINES OF LOW MOLECULAR WEIGHT WITH CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY
MX2013007537A (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
EP2555741A4 (en) SPRAYABLE COMPOSITION COMPRISING A POLYMER FILLED WITH HIGH MOLECULAR WEIGHT
BR112013028365A2 (pt) "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer".
UA101497C2 (ru) Конъюгаты фактора ix с увеличенным временем полужизни
EP2557120A4 (en) COMPOSITION FOR FORMING A HEAT-HARDENED FILM WITH LIGHTING ORIENTATION CHARACTERISTICS
WO2013186632A3 (en) Conjugates of biologically active molecules to functionalized polymers
EA201270186A1 (ru) Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений
IN2014CN03735A (pl)
IN2014DN07199A (pl)
BR112014004644A2 (pt) polímeros funcionalizados com lactonas ou tiolactonas contendo um grupo amino protegido